HMGB1 and pulmonary fibrosis: For pulmonary fibrosis, Hamada et al. discovered that EP treatment also had protective effects against bleomycin-induced lung injury in a rat model, possibly by inhibiting the level of high-mobility group box 1 (HMGB1) [14].